COMMUNIQUÉS West-GlobeNewswire

-
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
21/09/2017 - 00:23 -
ProtectMyPeople - A New Group Life Insurance Comparison Site - Launches for UK Small and Medium Business Owners
20/09/2017 - 18:48 -
GENFIT : Risque de confusion entre elafibranor, candidat médicament de type PPAR alpha/delta (Phase 3), et lanifibranor, composé de type PPAR a/d/gamma (Phase 2)
20/09/2017 - 18:24 -
GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor
20/09/2017 - 18:24 -
Summit Therapeutics plc : Holding(s) in Company
20/09/2017 - 17:15 -
Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board
20/09/2017 - 15:03 -
Optalysys, Ltd. Raises $4 Million Seed Round to Break Bottlenecks in Genomic Research and Big Data Analysis
20/09/2017 - 15:00 -
Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27
20/09/2017 - 14:00 -
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
20/09/2017 - 14:00 -
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
20/09/2017 - 12:58 -
Sanofi et Alnylam rapportent les premiers résultats positifs de l'étude de phase 3 APOLLO consacrée au patisiran dans le traitement de la polyneuropathie amyloïde familiale à la transthyrétine
20/09/2017 - 12:58 -
Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer
20/09/2017 - 11:24 -
Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD
20/09/2017 - 08:00 -
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
20/09/2017 - 07:15 -
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia
20/09/2017 - 07:00 -
Bone Therapeutics SA : announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis
20/09/2017 - 07:00 -
Bone Therapeutics SA : Annonce que l'ensemble des patients ont satisfait au critère principal d'évaluation de l'analyse intérimaire de la Phase I/IIA avec ALLOB® dans les fractures avec retard de c...
20/09/2017 - 07:00 -
Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference
19/09/2017 - 22:05 -
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress
19/09/2017 - 22:05
Pages